Canadian Biomaterials Society
La Société Canadienne des Biomatériaux

Dear CBS Members, As you are aware, the COVID-19 pandemic has caused numerous disruptions around the world, and scheduled conferences are being either postponed or canceled...

We are very pleased to inform you that Dr. Paul Santerre has been selected by the Board of Directors of the Canadian Biomaterials Society CBS as the next recipient of the CBS Lifetime Achievement Award , acknowledging his outstanding contributions to our Society...

CBS is pleased to offer travel awards to assist students and post-doctoral fellows who are CBS members to present their accepted oral or poster abstracts at the 11th World Biomaterials Congress this May in Glasgow, Scotland...

The Fall 2019 edition of the CBS Newsletter is now available. Read about the latest initiatives from CBS, look back at the Quebec City CBS Annual Meeting and look ahead to WBC 2020 coming up this May in Glasgow, find out more about our very active student chapters across the country, meet the new CBS Senior Board Members and President-Elect, and learn more about the many award opportunities provided by CBS...

Ureteral stents are extensively used in patients with obstructive urologic disorder to maintain a ureteral opening thus optimizing the flow of urine1...

Purpose The objective of this project was to deliver a unique malleable DNA-based hydrogel scaffold that can easily be injected by orthopedic surgeons, will set and integrate to the injured site after placement, and will be resorbed over time as it induces rapid in situ tissue regeneration via sustained delivery of osteoinductive drugs...

Surgical sutures are the gold-standard wound closure materials for centuries. However, they might induce tissue drag, damaging and dissecting delicate and fragile soft tissues and blood vessels, and cause body fluid air leakage...

Tissue engineering scaffolds promote tissue regeneration by providing a structure where regeneration is encouraged...

Current therapies with tyrosine kinase inhibitors such as Imatinib against Chronic Myeloid Leukemia CML inhibit production of 99 of fast-dividing cells, which are mostly the ones that remain in suspension through out the circulation system...